Howard Lee

Biography

Dr. Howard Lee is a Professor, Seoul National University School of Medicine and Hospital, affiliated with the Department of Clinical Pharmacology and Therapeutics. Dr. Lee is also appointed at the Department of Transdisciplinary Studies, Graduate School of Convergence Science and Technology, Seoul National University. Dr. Lee serves as Head of Global Strategy and Planning, Clinical Trials Center, SNUH. Dr. Lee is a board-certified physician in Family Medicine and Clinical Pharmacology and holds a Ph.D. in Epidemiology. He completed a fellowship in Clinical Pharmacology at the Center for Drug Development Science, Department of Pharmacology at the Georgetown University School of Medicine where he subsequently served as an Assistant Professor of Medicine. Dr. Lee came to the Department with an interesting mix of careers in academia, industry, and government. Prior to his appointment in Seoul National University Hospital and College of Medicine in September 2012, he had served as faculty in three US-based universities including the University of California San Francisco, the University of Pittsburgh, and Georgetown University. Dr. Lee was the co-PI for clinical pharmacology of the Washington Obstetric Pharmacology Research Unit Network grant (NIH HD-03-017) affiliated with Georgetown University Medical Center, and has also served as the co-I of the Collaborative Pediatric Pharmacology Research Unit Network grant (NIH HD-03-001). Dr. Lee was the PI of the Merck Foundation Grant, entitled “A Systematic Policy Analysis to Identify Key Strategies for Implementing Good Review Practices into the Korea Food and Drug Administration”. Dr. Lee is well-versed in pharmacometrics, clinical trials design, drug development science, and drug regulations (Korea and the US).

Research Interest

First-in-human study of an anti-obesity drug, AMS-based microdosing and microtracer studies, pharmacokinetic-pharmacodynamic modeling of an angiotensin receptor blocker using 24-hour ambulatory blood pressure monitoring, and regulatory issues related biosimilar products.